Challenges in the management of infections due to carbapenem-resistant Enterobacteriaceae

Infection Control and Hospital Epidemiology

Volumn 35, Issue 4, 2014, Pages 437-439

  Drekonja, Dimitri M ^a,b   Beekmann, Susan E ^c   Elliott, Sean ^d   Mukundan, Deepa ^e   Polenakovik, Hari ^f   Rosenthal, Marnie E ^g   Tamma, Pranita D ^h   Polgreen, Philip M ^c   Weissman, Scott J ⁱ  

^a Minneapolis Veterans Affairs Health Care System   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e MEDICAL COLLEGE OF OHIO   (United States)

^f WRIGHT STATE UNIVERSITY   (United States)

^g JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; CARBAPENEM DERIVATIVE;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CHRONIC KIDNEY DISEASE; CITROBACTER; CLINICAL ARTICLE; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KLEBSIELLA; MALE; PANCREATITIS; PROTEUS; PSEUDOMONAS; RISK FACTOR; SALMONELLA; SERRATIA; TRAVEL; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; MICROBIAL SENSITIVITY TEST; QUESTIONNAIRE;

ADULT; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; QUESTIONNAIRES;

EID: 84895782393     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/675604     Document Type: Article

References (8)

1. Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013;62(9):165-170.
2. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1-12.
3. Emerging Infections Network (EIN). Carbapenem-Resistant Enterobacteriaceae Infections: A Case Series. Iowa City, IA: EIN, 2012. http://www.int-med.uiowa.edu/Research/EIN/CREcaseseries _form.pdf.
4. Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;30(12):1279-1291.
5. Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 2010; 50(2):229-238.
6. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54(12):1699-1709.
7. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57(3):349-358.
8. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenemresistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch InternMed 2005;165(12): 1430-1435.